Michael Kaufman to Receptor Protein-Tyrosine Kinases
This is a "connection" page, showing publications Michael Kaufman has written about Receptor Protein-Tyrosine Kinases.
Connection Strength
0.347
-
Caldwell TM, Kaufman MD, Wise SC, Mi Ahn Y, Hood MM, Lu WP, Patt WC, Samarakoon T, Vogeti L, Vogeti S, Yates KM, Bulfer SL, Le Bourdonnec B, Smith BD, Flynn DL. Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors. Bioorg Med Chem Lett. 2022 10 15; 74:128929.
Score: 0.197
-
Powell NA, Hoffman JK, Ciske FL, Kaufman MD, Kohrt JT, Quin J, Sheehan DJ, Delaney A, Baxi SM, Catana C, McConnell P, Ohren J, Perrin LA, Edmunds JJ. Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15; 23(4):1046-50.
Score: 0.101
-
Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, Vogeti L, Vogeti S, Kaufman MD, Wise SC, Le Bourdonnec B, Smith BD, Flynn DL. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorg Med Chem Lett. 2022 10 15; 74:128928.
Score: 0.049